Lipella Pharmaceuticals (US:LIPO) Globenewswire·2025-06-25 19:15Core Viewpoint - Lipella Pharmaceuticals Inc. is committed to transparency and long-term value creation despite its recent delisting from the Nasdaq Capital Market, with ongoing clinical programs and plans for relisting on a national exchange [2][3]. Company Overview - Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating existing generic drugs to address diseases with significant unmet needs [4]. Delisting and Relisting Plans - The company expressed disappointment over the Nasdaq's decision to delist but emphasized that its underlying business remains strong and is actively pursuing relisting on a national exchange [3][6]. - Lipella is evaluating national exchanges that support early-stage innovation and intends to file an initial listing application soon [6]. Operational Status - The company remains fully operational, with clinical programs advancing as planned, and the delisting has not affected clinical timelines or research staffing [6]. Clinical Pipeline - Lipella's lead candidates, LP-310 for oral lichen planus and LP-10 for hemorrhagic cystitis, continue to show promising clinical progress, with final topline data from the Phase 2a trial of LP-310 expected in the second half of 2025 [6]. Financial Position - Lipella maintains a sound financial standing, with sufficient capital to support ongoing development programs and prudent fiscal management in place [6]. Shareholder Engagement - The company will continue to communicate with shareholders through SEC filings, press releases, and investor outreach, including participation in investor conferences and calls [6].